Drugs / ASC41
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05118516 | Nov → Dec 2021 | — | Gannex Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04845646 | Mar → Jun 2021 | NAFLD1 | Gannex Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04692025 | Dec 2020 → Jan 2021 | fatty liver disease, hyperlipidemia | Gannex Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04686994 | Dec 2020 → Jan 2021 | fatty liver disease, hyperlipidemia, morbid obesity | Gannex Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04527250 | Sep → Dec 2020 | — | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05118360 | Dec 2023 → Nov 2024 | metabolic dysfunction-associated steatohepatitis | Gannex Pharma Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05462353 | Sep 2022 → May 2025 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | Gannex Pharma Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC41 | “The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and...” NCT04686994 ↗7“One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.” NCT05118516 ↗ |
| Action | Activate | “ASC41, a THR beta agonist” NCT04686994 ↗ |
| Route | Oral | “ASC41 one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.” NCT04527250 ↗ |